Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT for Pollen Allergy in Children
NCT03375775Completed
- Sponsor
- Karolinska Institutet
- Start
- May 2017
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of alutard-sq in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Response to a Conjunctival Allergen Challenge at 36 months. Started May 2017; status: completed.
02
Drugs
alutard-sq
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT03375775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375775.